← Russell 3000 cross-section

TMCI TREACE MEDICAL CONCEPTS, INC.

Trailing twelve months to 2026-06-30 · as filed 2026-08-07, not restated
Healthcare

Scale

Market cap
$301m
Revenue TTM
$205m
Net income TTM
$-60m
Free cash flow
$-25m
Composite score
22.9
Sector rank
#2659

Valuation

P / E
EV / EBITDA
EV / sales
1.5
FCF yield
-8.32%
Earnings yield vs 10-yr
-24.49pp

Earnings yield vs 10-yr compares what the business earns per pound invested against the 4.73% a 10-year US Treasury note pays for no equity risk. Negative means you are paying up front for growth not yet delivered.

Quality and growth

Net margin
-29.0%
EBITDA margin
-22.1%
ROE
-87.9%
ROIC
-66.1%
Revenue growth
-4.0%

Insider activity, last 90 days

Net open-market
$0.64m
Buyers
1
Sellers
0

Open-market purchases and sales only. Grants, option exercises, gifts and shares withheld for tax are excluded: they are how people are paid, not what they think.

What management said

We primarily market and sell our products through a combination of a direct employee sales force and independent sales agencies and stocking distributors in the United States. While we continuously work with suppliers to mitigate higher costs and continue to invest in our direct sales channel, focused surgeon education training, and product innovations to build demand for our products, we expect these macroeconomic challenges to continue for the foreseeable future, which have impacted and likely will continue to impact the demand for our products and our results of operations. …TREACE MEDICAL CONCEPTS, INC., 10-Q, period ended 2026-06-30, filed 2026-08-07

Read the full passage →